Navigation Links
Sepsis Treatment Offers Lifesaving Potential
Date:6/16/2009

Blood-cleansing therapy used in Japan warrants further study: researchers

TUESDAY, June 16 (HealthDay News) -- A device designed to filter bacteria-produced toxins from the blood of patients with severe sepsis or septic shock appears to improve blood circulation and organ function and lower the risk of death, a preliminary study suggests.

Italian researchers tested whether using a polymyxin B fiber column -- an antibiotic-based hemoperfusion device -- with conventional therapy would improve patient outcomes. Polymyxin B is an antibiotic, and hemoperfusion is blood filtering to remove toxins.

The study included 64 patients with severe sepsis or septic shock who had emergency surgery for intra-abdominal infection. The patients were randomly selected to receive either conventional therapy or conventional therapy plus two sessions of polymyxin B hemoperfusion.

After 28 days, the death rate was 32 percent in the polymyxin B hemoperfusion group and 53 percent in the group that received conventional therapy alone.

The study appears in the June 17 issue of the Journal of the American Medical Association.

"Larger multicenter studies are indicated to confirm these encouraging findings in other patient populations," the Italian researchers wrote.

The therapy used in this study is common in Japan, but not in the United States, according to an accompanying editorial written by Dr. John A. Kellum, of the University of Pittsburgh Medical Center, and Dr. Shigehiko Uchino, of the Jikei University School of Medicine in Tokyo.

Even though preliminary, the findings "suggest a number of interesting hypotheses and should provoke further study. This is essential given the significant ongoing problem that sepsis represents," they wrote.

More information

The MedlinePlus Medical Encyclopedia has more about

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Scientists Probe Sepsis Deadly Secrets
2. Blacks More Likely to Die of Severe Sepsis
3. Research May Yield New Weapons Against Sepsis
4. Customized treatments for sepsis lower treatment time and reduce length of ICU stays
5. Ashwell receptor reduces mortality during sepsis
6. Educational Drive Cut Death Rate From Sepsis
7. Medical Simulation Corporation Introduces Sepsis Quality Initiative Program
8. Sepsis Therapy in Preemies Fails to Boost Survival
9. Children's National Research Links Platelets to Sepsis-Related Organ Failure
10. Vanderbilt researchers pioneer an advanced sepsis detection and management system
11. New treatment effective in counteracting cocaine-induced symptoms

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sepsis Treatment Offers Lifesaving Potential 
Sepsis Treatment Offers Lifesaving Potential
(Date:11/21/2009)...ill provides for an unprecedented expansion of fed...if it is not for preserving and protecting human l...ed." Charmaine Yoest ,, WASHINGTON, Nov. 21 ...fe Action President and CEO Dr. Charmaine Yoest re...ng the following statement: ,, "This was a pro...
(Date:11/21/2009)... NH based medical credentialing software company... form a partnerhsip with Amerinet, Inc., the leadi... will help to transform quality care within the he...) November 21, 2009 -- ISG Group, LLC, doing busin...ement with Amerinet Inc., a leading national healt...
(Date:11/21/2009)... Linwood Group ask whether there is a secret to ... London, UK (PRWEB) Novemb...o one in three of the adult UK population drinking...ohol-related liver disease*, it is hardly a surpri...ation programmes and residential centres for help....
(Date:11/20/2009)...., Nov. 20 Following a recall by U...moved from sale Shedd,s Country Crock ® Side ...untry Crock ® Side Dishes DELUXE Four Cheese ..., The following code dates and UPCs are affected: ...LUXE Cheddar Broccoli Rice 21 oz, UPC 027400218316...
(Date:11/20/2009)..., Israel, November 20 Ca...p://www.CVSLMEDICAL.COM , a leading,developer of a...nnounced that,the company,s Board of Directors has..., Canada and the Far East for its proprietary next...ll angioplasty (PCTA) procedures. , Cardi...
Breaking Medicine News(10 mins):Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2
...tients to be remotely monitored through XTend,s Di..., SUN VALLEY, Calif., Feb. 14 XTend Medical,Corp...mpany has begun a,remote diabetic monitoring progr...emotely monitor diabetic patients through the XTen...
...nvestments Totaled Approximately $2.2 Billion, Ven...o Range between $2.75 ...S EIGHT PERCENT TO $0.5125 PER SHARE, LOUISVILLE,...d common share rose ten percent to,$2.69, compared...
...ferers Can Enjoy a Romantic Valentine,s Day With ...LE, Feb. 13 , WHO: The 60 million Americans... don,t have to worry about a painful sore deraili... adhesive patch, has been shown in a peer-re...
...exico, among the choices for 2008, SEATTLE, Feb. ...lcanoes of Mexico" -- highlights the 2008 Climb to... Cancer Research Center., The 11th annual Climb h...,343 feet). Both trips will be led by,professional...
...3 Matrixx Initiatives, Inc.,(Nasdaq: MTXX ), an ...and,markets products that provide consumers with "...on Wednesday February 20, 2008, at the Roth,Capita... http://www.matrixxinc.com . Interested parties,sh...
...Feb. 13 Valentine,s Day is,not just for lovers. T...ers, St. Valentine, takes on greater meaning when ...sy -- a common neurological condition that,causes ...Valentine is connected to epilepsy because,the nam...
Other Medicine News:Health News:XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program 2Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 2Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 3Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 4Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 5Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 6Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 7Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 8Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 9Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 10Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 11Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 12Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 13Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 14Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 15Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 16Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 17Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 18Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 19Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 20Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 21Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 22Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 23Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 24Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 25Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 26Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 27Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 28Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 29Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 30Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 31Health News:Pucker Up Without the Pain 2Health News:Climb to Fight Breast Cancer Offers Peaks for Every Skill Level 2Health News:Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference 2
(Date:11/20/2009)...-- ,, Reportlinker.com announces that a new mar... ,, Global Markets for Breast Biopsy Devices 2...Global-Markets-for-Breast-Biopsy-Devices-2009.html...ampaign=prnewswire ,, The global markets for ...ore needle market and vacuum assisted breast biops...
(Date:11/20/2009)...tCall/ -- Cyberonics, Inc. (Nasdaq: CYBX ) today ...utive Officer, and Greg Browne, Chief Financial Of...ay Health Care Conference in New York on Wednesday...e session and webcast will be audio only and no fo... host a webcast of the presentation live and by re...
(Date:11/19/2009).../ -- Warner Chilcott plc (Nasdaq: WCRX ) today an...condary offering of 20,000,000 of its ordinary sha... The selling shareholders include funds affiliated... J.P. Morgan Partners (advised by CCMP Capital) an...itutional investors and members of the Company,s s...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Placental precursor stem cells require testosterone free environment to survive 10574 1Placental precursor stem cells require testosterone free environment to survive 10574 2American Physiological Society endorses report on random source dogs and cats 10569 1American Physiological Society endorses report on random source dogs and cats 10569 2American Physiological Society endorses report on random source dogs and cats 10569 3The Breema Center Offers Bodywork Mini Sessions and Demonstrations at the San Francisco Green Festival 60315 1The Breema Center Offers Bodywork Mini Sessions and Demonstrations at the San Francisco Green Festival 60315 2
...t from,Schering-Plough, Roche today affirmed the v...ination with ribavirin as the market-leading,treat...States and globally.,Despite clear biases in the d...d patients taking Peg-Intron(TM) (peginterferon al...reduction protocol - the study results have,shown ...
...ay, SOUTH SAN FRANCISCO, Calif., Jan. 14 Cell,Ge...the Independent Data,Monitoring Committee (IDMC) f...cal trials of GVAX immunotherapy for prostate canc...nd has recommended that the study continue.,This e...mine whether the,study should continue to completi...
Other Medicine Technology:Roche responds to announcement of 'IDEAL' hepatitis C trial results 2Roche responds to announcement of 'IDEAL' hepatitis C trial results 3Roche responds to announcement of 'IDEAL' hepatitis C trial results 4Roche responds to announcement of 'IDEAL' hepatitis C trial results 5Roche responds to announcement of 'IDEAL' hepatitis C trial results 6Roche responds to announcement of 'IDEAL' hepatitis C trial results 7Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 2Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 3Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 4
Aaron 800-EU
Sabre 180, 100V, 50Hz/60Hz
Sabre 2400, 240V, 50Hz
Sabre 2400, 110V, 60Hz
Medicine Products: